子宮托市場機會、成長動力、產業趨勢分析與 2025 - 2034 年預測

2024 年全球子宮托市場價值為 4.475 億美元，預計 2025 年至 2034 年期間將以 4.8% 的複合年成長率穩步成長。 這一成長主要得益於盆腔器官脫垂 (POP) 和尿失禁患病率的不斷上升、 這一成長主要得益於盆腔器官脫垂 (POP) 和尿失禁患病率的不斷上升、對治療和治療這一重要性的非持續性提高對政府的重要影響方案。

市場按類型細分，其中環形子宮托佔據領先地位，在 2024 年佔據 51.6% 的市場佔有率。它的設計減少了刺激並允許長時間使用，使其成為臨床環境中的首選，並有助於其廣泛接受。

按最終用戶分類，醫院成為領先細分市場，到 2024 年佔據了 46.2% 的市場佔有率。這些機構提供手術和非手術子宮托治療，以滿足不同嚴重程度患者的需求。他們處理複雜病例和提供必要後續護理的能力進一步鞏固了他們在子宮托市場的主導地位。

在美國，子宮托市場價值在 2024 年達到 1.697 億美元，並持續展現出強勁的成長潛力。骨盆腔疾病的增多，以及肥胖等與生活方式相關的健康狀況，推動了對子宮托作為有效、非侵入性治療方案的需求不斷增加。醫療保健管道的擴大和不斷提高人們對骨盆健康問題的認知的努力正在促進全國市場的持續成長。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 骨盆腔器官脫垂及尿失禁盛行率不斷上升
    • 對及時診斷和治療的認知不斷提高
    • 非侵入性治療方案的採用率不斷提高
    • 政府對婦女健康計畫的支持不斷增加
  • 產業陷阱與挑戰
    • 社會恥辱與心理障礙
    • 擔心長期使用會導致感染風險
• 成長潛力分析
• 專利分析
• 差距分析
• 監管格局
• 技術格局
• 未來市場趨勢
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略展望

第 5 章：市場估計與預測：按類型，2021 年至 2034 年

• 主要趨勢
• 戒指
• 油炸圈餅
• 蓋爾霍恩
• 其他類型

第 6 章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 輕度骨盆腔器官脫垂
• 壓力性尿失禁
• 嚴重骨盆腔器官脫垂
• 其他應用

第 7 章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 醫院
• 門診手術中心
• 診所
• 其他最終用戶

第 8 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Artisan Medical
• Bioteque America
• Bliss GVS Pharma
• Bray Group (Ethos Partners)
• Coloplast Group
• Contiform International
• CooperSurgical
• Dr. Arabin
• Integra Lifesciences
• MedGyn Products
• Novomed group (Gyneas)
• Panpac Medical
• Personal Medical
• Smiths Group
• Sugar International

The Global Pessary Market was valued at USD 447.5 million in 2024 and is projected to experience steady growth at a CAGR of 4.8% from 2025 to 2034. This growth is primarily driven by the increasing prevalence of pelvic organ prolapse (POP) and urinary incontinence, heightened awareness about the importance of timely diagnosis and treatment, growing preference for non-invasive therapy options, and strengthened government initiatives supporting women's health programs.

The market is segmented by type, with the ring pessary leading the way, accounting for 51.6% of the market share in 2024. The ring pessary's continued dominance can be attributed to its versatility, ease of use, and lightweight comfort, making it ideal for individuals suffering from mild to moderate prolapse and stress urinary incontinence. Its design reduces irritation and allows for prolonged use, making it a favored choice in clinical settings and contributing to its widespread acceptance.

By end user, hospitals emerged as the leading segment, capturing 46.2% of the market share in 2024. Hospitals play a pivotal role in diagnosing, managing, and treating pelvic floor disorders such as POP and stress urinary incontinence. These institutions offer both surgical and non-surgical pessary treatments, catering to patients with varying levels of severity. Their ability to handle complex cases and provide essential follow-up care further reinforces their dominance in the pessary market.

In the United States, the pessary market was valued at USD 169.7 million in 2024 and continues to show strong growth potential. The rise in pelvic disorders, alongside lifestyle-related health conditions like obesity, is driving the increasing demand for pessaries as effective, non-invasive treatment solutions. The expansion of healthcare access and ongoing efforts to raise awareness about pelvic health issues are contributing to the continued market growth across the country.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of pelvic organ prolapse and urinary incontinence
    • 3.2.1.2 Growing awareness towards timely diagnosis and treatment
    • 3.2.1.3 Increasing adoption of non-invasive treatment options
    • 3.2.1.4 Growing government support in women health programs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Social stigma and psychological barrier
    • 3.2.2.2 Concerns related to risk of infections due to prolonged use
• 3.3 Growth potential analysis
• 3.4 Patent analysis
• 3.5 Gap analysis
• 3.6 Regulatory landscape
• 3.7 Technological landscape
• 3.8 Future market trends
• 3.9 Porter’s analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy outlook

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Ring
• 5.3 Donut
• 5.4 Gellhorn
• 5.5 Other types

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Mild pelvic organ prolapse
• 6.3 Stress urinary incontinence
• 6.4 Severe pelvic organ prolapse
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Clinics
• 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Artisan Medical
• 9.2 Bioteque America
• 9.3 Bliss GVS Pharma
• 9.4 Bray Group (Ethos Partners)
• 9.5 Coloplast Group
• 9.6 Contiform International
• 9.7 CooperSurgical
• 9.8 Dr. Arabin
• 9.9 Integra Lifesciences
• 9.10 MedGyn Products
• 9.11 Novomed group (Gyneas)
• 9.12 Panpac Medical
• 9.13 Personal Medical
• 9.14 Smiths Group
• 9.15 Sugar International